Device: Desktop
R&D Portfolio and Pipeline
Drug candidates
Indications
Discovery
Preclinical Development
Clinical Phase 1
Clinical Phase 2
Clinical Phase 3
Patent
AEF0117
for cannabis-related
disorders
disorders
AEF0217
for cognitive
disorders
disorders
New<br>CB<sub>1</sub>-SSi
for other cannabinoid-
dependent diseases
dependent diseases
AEF0117
for cannabis-related disorders
Stage:
Clinical phase 2
AEF0117
for cannabis-related disorders
Stage:
Clinical phase 2
AEF0117
for cannabis-related disorders
AEF0217
for cognitive disorders
Stage:
Clinical phase 1
AEF0217
for cognitive disorders
Stage:
Clinical phase 1
AEF0217
for cognitive disorders
Stage:
Discovery
New
CB1-SSi
CB1-SSi
for other cannabinoid-dependent diseases
Stage:
Discovery
New
CB1-SSi
CB1-SSi
for other cannabinoid-dependent diseases
Stage:
Discovery
New
CB1-SSi
CB1-SSi
for other cannabinoid-dependent diseases
AEF0117
for cannabis-related
disorders
disorders
AEF0117 has an open FDA IND and will enter phase 2b clinical trials in the United States during the second trimester of 2022.
AEF0117 is a new molecular entity (NME) developed by Aelis Farma to treat the harmful effects of excessive cannabis use.
AEF0117's major characteristics:
•
High potency in inhibiting the effects of cannabis’ active ingredient, THC, in several animal species including primates without side effects on normal behavior.
•
Favorable ADMET profile, with good oral absorption, brain access, long half-life and no toxic or adverse effects identified to date (Therapeutic index >13,000)
•
Good pharmacokinetic, safety and efficacy profile in healthy volunteers and cannabis addicts.
The clinical development of AEF0117 is supported by grants from NIDA-NIH (National Institute on Drug Abuse of the National Institute of Health, US).
AEF0217
for cognitive
disorders
disorders
AEF0217 entered phase 1 clinical trials in October 2021 in Europe.
AEF0217 is the second drug candidate developed by Aelis Farma. It is specifically designed for the treatment of cognitive deficits.
AEF0217's major characteristics:
•
High potency in reversing cognitive deficits in validated translational models of Down syndrome, Fragile X syndrome and aging related cognitive impairments.
•
No identifiable behavioral side effects even in fragile trisomic and aged mice.
•
Very favorable ADMET profile, with good oral absorption, brain access, long half-life and a good tolerability (therapeutic index = 640).
Clinical development of AEF0217, for which its first therapeutic indication is the cognitive deficits in Down syndrome, is supported by a grant from the EU (Horizon Programme H2020, Grant N° 899986).
New
CB1-SSi
CB1-SSi
for other cannabinoid-
dependent diseases
dependent diseases
Aelis Farma’s platform provides new Signaling Specific inhibitors of the CB1 receptor.
New CB1-SSi are New Molecular Entities (NME) with an original structure and improved pharmacodynamic properties, which will provide drug candidates for the treatment of other CB1-dependent diseases, including several orphan diseases.
